5:17 PM
 | 
Mar 24, 2014
 |  BC Extra  |  Company News

NICE rebuffs Xofigo

U.K.'s NICE issued a Xofigo radium-223 dichloride from Bayer AG (Xetra:BAYN) to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases -- its approved indication in the EU....

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >